Teza Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Teza Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,941	Closed	-$215K	–	455
2025 Q1	$215K	Buy	5,941 +84	+1%	+$3.5K	0.1%	344
2024 Q4	$246K	Buy	5,857 +993	+20%	+$49.3K	0.04%	397
2024 Q3	$270K	Buy	+4,864	New	+$248K	0.03%	499
2024 Q2	–	Sell	-5,293	Closed	-$247K	–	726
2024 Q1	$247K	Buy	+5,293	New	+$250K	0.03%	475
2023 Q1	–	Sell	-6,707	Closed	-$311K	–	674
2022 Q4	$311K	Buy	+6,707	New	+$264K	0.06%	438

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Teza Capital Management's RARE Position: Q2 2025 in Review

Teza Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 5,941 shares — an estimated $215K sold.

Teza Capital Management first reported a position in RARE in Q4 2022 and held it in 5 quarters. The position peaked at $311K in Q4 2022. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

Teza Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
Teza Capital Management sold 5,941 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $215K.
Teza Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and held it in 5 quarters.
Teza Capital Management's Ultragenyx Pharmaceutical position peaked at $311K in Q4 2022.
309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on Teza Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.